SBI Healthcare Opportunities Fund
The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Growthvine rating: 5/5 — ranked #8 of 87 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹541.28 (as of 2026-11-13) |
|---|
| AUM | ₹5,870 Cr |
|---|
| Expense ratio | 1.57% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Tanmaya Desai |
|---|
| Exit load | 0.5% for redemption within 15 days |
|---|
Performance & risk
| 5-year annualised return | 17.63% |
|---|
| Sharpe ratio | 1.16 |
|---|
| Standard deviation | 14.37% |
|---|
| Max drawdown | −63.37% |
|---|
| Alpha | 2.28 |
|---|
| Beta | 0.86 |
|---|
Over 5 years, captured 95.7% of NIFTY Pharma's upside and 80.5% of its downside.
Market cap allocation
| Large cap | 33.3% |
|---|
| Mid cap | 27.1% |
|---|
| Small cap | 39.6% |
|---|
Concentration
| Top 5 holdings | 33.7% |
|---|
| Top 10 holdings | 53.1% |
|---|
| Total holdings | 37 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 10.6%
- Divis Laboratories Ltd. — 8.4%
- Max Healthcare Institute Limited — 5.0%
- ACUTAAS CHEMICALS LIMITED — 4.9%
- Apollo Hospitals Enterprises Ltd. — 4.9%
- Laurus Labs Limited — 4.8%
- Cipla Ltd. — 4.4%
- TREPS — 4.1%
- Torrent Pharmaceuticals Ltd. — 4.1%
- Aurobindo Pharma Ltd. — 3.1%
Top sectors
- Pharma & Biotech — 61.8%
- Healthcare — 30.9%
- Chemicals — 4.4%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 28.4% | Q1 (Top) | #3 of 76 |
| 2025 | −3.5% | Q3 | #48 of 69 |
| 2024 | 42.2% | Q1 (Top) | #5 of 58 |
| 2023 | 38.2% | Q2 | #20 of 48 |
| 2022 | −6.0% | Q3 | #33 of 46 |